Brought to you by 
Neuromed grants Covidien US rights to Exalgo
06 Apr 2010
Executive Summary
Pain therapeutics developer Neuromed and its Neuromed Development subsidiary have granted Covidien's Mallinckrodt pharmaceuticals division rights to sell Exalgo (hydromorphone) extended release tablets in the US.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neuromed grants Covidien US rights to Exalgo
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice